← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #687 OF 1,000 MOST-CITED

Written procedures describing in detail

FDA cited this observation 24 times across 22 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs24
BY FISCAL YEAR
FY20253
FY20241
FY20212
FY20201
FY20194
FY20186
FY20177

How FDA worded it — real examples

There is a lack of written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, examination and testing of labeling and packaging materials.

Lexia LLC · Franklin, Tennessee · Drugs · 2025-09-29

There is a lack of written procedures describing in sufficient detail the handling of labeling and packaging materials.

L. Perrigo Company · Allegan, Michigan · Drugs · 2025-03-19

There is a lack of written procedures describing in sufficient detail the identification, storage, handling and examination of labeling and packaging materials.

Image Supply Inc · Lumberton, North Carolina · Drugs · 2025-01-08

There is a lack of written procedures describing in sufficient detail the receipt, sampling and examination of labeling and packaging materials.

FANCYSTAGE, UNIPESSOAL, LDA. · Trofa · Drugs · 2024-01-26

There is a lack of written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, examination and testing of labeling and packaging materials.

Spa De Soleil, Inc. · Sun Valley, California · Drugs · 2021-09-17

There is a lack of written procedures describing in sufficient detail the examination of labeling and packaging materials.

Sircle Laboratories, L.L.C. · Madison, Mississippi · Drugs · 2021-04-26

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality systemPharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →